These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21125730)

  • 21. Does CYP2C19 inhibition lead to clopidogrel thrombogenicity?
    Cohen MJ
    Med Hypotheses; 2011 Sep; 77(3):448-50. PubMed ID: 21719206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Interaction between clopidogrel and proton pump inhibitors].
    Harmsze AM; de Boer A; Boot H; Deneer VH; Heringa M; Mol PG; Schalekamp T; Verduijn MM; Verheugt FW; le Comte M
    Ned Tijdschr Geneeskd; 2011; 155(28):A2442. PubMed ID: 21771377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.
    Angiolillo DJ; Gibson CM; Cheng S; Ollier C; Nicolas O; Bergougnan L; Perrin L; LaCreta FP; Hurbin F; Dubar M
    Clin Pharmacol Ther; 2011 Jan; 89(1):65-74. PubMed ID: 20844485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition.
    Zhang H; Ragueneau-Majlessi I; Levy RH
    Drug Metab Lett; 2009 Dec; 3(4):287-9. PubMed ID: 19995331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical significance of interactions between clopidogrel and proton pump inhibitors].
    Kubica A; Koziński M; Grześk G; Goch A
    Kardiol Pol; 2011; 69(6):610-6. PubMed ID: 21678305
    [No Abstract]   [Full Text] [Related]  

  • 26. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Miao J; Liu R; Li Z
    N Engl J Med; 2009 May; 360(21):2250-1. PubMed ID: 19469033
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects.
    Hulot JS; Wuerzner G; Bachelot-Loza C; Azizi M; Blanchard A; Peyrard S; Funck-Brentano C; Gaussem P
    J Thromb Haemost; 2010 Mar; 8(3):610-3. PubMed ID: 20040040
    [No Abstract]   [Full Text] [Related]  

  • 28. Proton pump inhibitor and clopidogrel interaction: fact or fiction?
    Laine L; Hennekens C
    Am J Gastroenterol; 2010 Jan; 105(1):34-41. PubMed ID: 19904241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-platelet therapy and managing ulcer risk.
    Chan FK
    J Gastroenterol Hepatol; 2012 Feb; 27(2):195-9. PubMed ID: 22142030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
    Wu CY; Chan FK; Wu MS; Kuo KN; Wang CB; Tsao CR; Lin JT
    Gastroenterology; 2010 Oct; 139(4):1165-71. PubMed ID: 20600012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Proton pump inhibitors and clopidogrel: a hazardous association?].
    Szymezak J; Gaussem P
    Rev Med Interne; 2013 Feb; 34(2):99-104. PubMed ID: 23200799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for interaction between clopidogrel and proton-pump inhibitors.
    Chua D; Lo A; Jung J
    Am J Health Syst Pharm; 2010 Apr; 67(8):604-5; author reply 605-6. PubMed ID: 20360584
    [No Abstract]   [Full Text] [Related]  

  • 33. Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy.
    Fernando H; Dart AM; Peter K; Shaw JA
    Thromb Haemost; 2011 Jun; 105(6):933-44. PubMed ID: 21544314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacogenetics of clopidogrel and its clinical significance].
    Panchenko EP; Komarov AL
    Kardiologiia; 2012; 52(9):44-52. PubMed ID: 23098546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent safety concerns with proton pump inhibitors.
    Chen J; Yuan YC; Leontiadis GI; Howden CW
    J Clin Gastroenterol; 2012 Feb; 46(2):93-114. PubMed ID: 22227731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A current problem for regulators. Clopidogrel and pharmacokinetics].
    Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):360-7. PubMed ID: 19572363
    [No Abstract]   [Full Text] [Related]  

  • 37. Controversy of proton pump inhibitor and clopidogrel interaction: a review.
    Tan HJ
    J Dig Dis; 2010 Dec; 11(6):334-42. PubMed ID: 21091895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel.
    Kwok CS; Loke YK
    Aliment Pharmacol Ther; 2010 Apr; 31(8):810-23. PubMed ID: 20102352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clopidogrel and proton pump inhibitors: a clinically meaningful interaction?
    Gerhard T
    Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):214-8. PubMed ID: 21254294
    [No Abstract]   [Full Text] [Related]  

  • 40. What's new about clopidogrel.
    Cialdella P; Gustapane M; Camaioni C; Biasucci LM
    Minerva Cardioangiol; 2013 Dec; 61(6):683-9. PubMed ID: 24253460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.